C4 Therapeutics Inc (CCCC)
6.74
+0.31
(+4.82%)
USD |
NASDAQ |
May 03, 16:00
6.91
+0.17
(+2.52%)
After-Hours: 20:00
C4 Therapeutics Debt to Equity Ratio: 0.00 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.0442 |
| March 31, 2023 | 0.0416 |
| December 31, 2022 | 0.0397 |
| September 30, 2022 | 0.0355 |
| June 30, 2022 | 0.0323 |
| March 31, 2022 | 0.03 |
| December 31, 2021 | 0.0276 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.0266 |
| June 30, 2021 | 0.025 |
| March 31, 2021 | 0.0388 |
| December 31, 2020 | 0.0358 |
| September 30, 2020 | -0.0633 |
| June 30, 2020 | 0.0782 |
| March 31, 2020 | |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.0633
Minimum
Sep 2020
0.0782
Maximum
Jun 2020
0.0245
Average
0.0312
Median
Debt to Equity Ratio Benchmarks
| Exact Sciences Corp | 0.7517 |
| Alector Inc | 0.00 |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.00 |
| IGC Pharma Inc | 0.0152 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 376.45M |
| Total Liabilities (Quarterly) | 130.34M |
| Shareholders Equity (Quarterly) | 246.11M |
| Current Ratio | 6.341 |
| Net Debt Paydown Yield | 0.66% |